Next Article in Journal
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
Next Article in Special Issue
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
Previous Article in Journal
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches
Previous Article in Special Issue
Primary Gastrointestinal T-Cell Lymphoma and Indolent Lymphoproliferative Disorders: Practical Diagnostic and Treatment Approaches
 
 
Review

Article Versions Notes

Cancers 2022, 14(3), 597; https://doi.org/10.3390/cancers14030597
Action Date Notes Link
article xml file uploaded 25 January 2022 11:30 CET Original file -
article xml uploaded. 25 January 2022 11:30 CET Update -
article pdf uploaded. 25 January 2022 11:30 CET Version of Record -
article xml file uploaded 25 January 2022 11:31 CET Update -
article xml uploaded. 25 January 2022 11:31 CET Update https://www.mdpi.com/2072-6694/14/3/597/xml
article pdf uploaded. 25 January 2022 11:31 CET Updated version of record https://www.mdpi.com/2072-6694/14/3/597/pdf
article html file updated 25 January 2022 11:32 CET Original file -
article html file updated 25 January 2022 11:32 CET Update -
article html file updated 25 January 2022 11:32 CET Update -
article html file updated 25 January 2022 11:33 CET Update -
article html file updated 25 January 2022 11:33 CET Update -
article html file updated 25 January 2022 11:33 CET Update -
article html file updated 31 July 2022 05:58 CEST Update https://www.mdpi.com/2072-6694/14/3/597/html
Back to TopTop